Go Pro

This company recently went public with an IPO on Friday, August 7th 2026. They issued 9,375,000 shares at $15.00 - $17.00 per share. We will continue to update data for BLSM as it becomes available.

BlossomHill Therapeutics (BLSM) 10K Form and Latest SEC Filings 2026

$15.99 -0.01 (-0.06%)
As of 04:00 PM Eastern

Latest BlossomHill Therapeutics SEC Filings & Recent Activity

BlossomHill Therapeutics (NASDAQ:BLSM) has submitted 32+ documents to the U.S. Securities and Exchange Commission (SEC) since 2021. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on August 10, 2026.

8-K
BlossomHill Therapeutics Files Current Report on Aug. 10, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

BlossomHill Therapeutics SEC Filing History

Browse BlossomHill Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
08/10/2026 5:23 PM
BlossomHill Therapeutics (1839970) Issuer
Li Yishan (1772233) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 5:24 PM
BlossomHill Therapeutics (1839970) Issuer
Oxnard Geoffrey Raymond (2144320) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 5:26 PM
BlossomHill Therapeutics (1839970) Issuer
Liptak Vincent Paul (2143905) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 5:27 PM
BlossomHill Therapeutics (1839970) Issuer
Keyes Jason A (1678152) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 5:29 PM
Agrawal Sundeep (1840599) Reporting
BlossomHill Therapeutics (1839970) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 5:32 PM
BlossomHill Therapeutics (1839970) Issuer
Chen Bihua (1599214) Reporting
Cormorant Asset Management, LP (1583977) Reporting
Cormorant Global Healthcare Master Fund, LP (1618442) Reporting
Cormorant Private Healthcare Fund III LP (1817320) Reporting
Cormorant Private Healthcare Fund V LP (1969296) Reporting
Cormorant Private Healthcare Fund VI, LP (2098185) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 5:33 PM
BlossomHill Therapeutics (1839970) Issuer
GORDON CARL L (1282930) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 5:35 PM
BlossomHill Therapeutics (1839970) Issuer
Schmid John P. (1478916) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 5:22 PM
BlossomHill Therapeutics (1839970) Issuer
Cui Jingrong Jean (1772259) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 3:48 PM
BlossomHill Therapeutics (1839970) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
08/10/2026 3:01 PM
BlossomHill Therapeutics (1839970) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2026 11:15 PM
BlossomHill Therapeutics (1839970) Filer
Form EFFECT
08/06/2026 8:09 PM
BlossomHill Therapeutics (1839970) Issuer
ORBIMED ADVISORS LLC (1055951) Reporting
OrbiMed Capital GP VIII LLC (1845804) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:38 PM
BlossomHill Therapeutics (1839970) Issuer
Liptak Vincent Paul (2143905) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:39 PM
BlossomHill Therapeutics (1839970) Issuer
Chen Bihua (1599214) Reporting
Cormorant Asset Management, LP (1583977) Reporting
Cormorant Global Healthcare Master Fund, LP (1618442) Reporting
Cormorant Private Healthcare Fund III LP (1817320) Reporting
Cormorant Private Healthcare Fund V LP (1969296) Reporting
Cormorant Private Healthcare Fund VI, LP (2098185) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:43 PM
BlossomHill Therapeutics (1839970) Issuer
GORDON CARL L (1282930) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:46 PM
Agrawal Sundeep (1840599) Reporting
BlossomHill Therapeutics (1839970) Issuer
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:47 PM
BlossomHill Therapeutics (1839970) Issuer
GUJRATHI SHEILA (1575202) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:48 PM
BlossomHill Therapeutics (1839970) Issuer
Schmid John P. (1478916) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:30 PM
BlossomHill Therapeutics (1839970) Issuer
Cui Jingrong Jean (1772259) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:31 PM
BlossomHill Therapeutics (1839970) Issuer
Li Yishan (1772233) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:35 PM
BlossomHill Therapeutics (1839970) Issuer
Keyes Jason A (1678152) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 7:37 PM
BlossomHill Therapeutics (1839970) Issuer
Oxnard Geoffrey Raymond (2144320) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/06/2026 6:48 PM
BlossomHill Therapeutics (1839970) Filer
Form S-1MEF
08/06/2026 4:17 PM
BlossomHill Therapeutics (1839970) Filer
Form CERT
08/04/2026 3:41 PM
BlossomHill Therapeutics (1839970) Filer
Form 8-A12B
08/03/2026 5:03 AM
BlossomHill Therapeutics (1839970) Filer
Form S-1/A
07/16/2026 7:13 PM
BlossomHill Therapeutics (1839970) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/10/2025 10:58 AM
BlossomHill Therapeutics (1839970) Filer
Form D
Notice of Exempt Offering of Securities 
(Data available from 1/1/2016 forward)

BlossomHill Therapeutics SEC Filings - Frequently Asked Questions

BlossomHill Therapeutics (BLSM) has submitted 32+ filings to the SEC since 2021. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 4 submitted on August 10, 2026. This was an insider ownership change filed by 4 - BlossomHill Therapeutics, Inc. (0001839970) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:BLSM) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners